Drug Table - Hormone Therapy Flashcards Preview

Pharm Drug Table > Drug Table - Hormone Therapy > Flashcards

Flashcards in Drug Table - Hormone Therapy Deck (39)
Loading flashcards...
1
Q

Prednisone (Meticorten) Class

A

Glucocorticoids

2
Q

Prednisone (Meticorten) Mechanism

A

Inhibit mitosis in lymphocytes

3
Q

Prednisone (Meticorten) Therapeutics

A

ALL; combination for Hodgkin’s, non-

Hodkin’s, multiple myeloma, and CLL

4
Q

Dexamethasone (Decadron) Class

A

Glucocorticoids

5
Q

Dexamethasone (Decadron) Mechanism

A

Inhibit mitosis in lymphocytes

6
Q

Dexamethasone (Decadron) Therapeutics

A

Reduces edema in brain and spinal

cord tumors with radiation therapy

7
Q

Tamoxifen (Soltamox) Class

A

Selective
estrogen-receptor
modulators
(SERMs)

8
Q

Tamoxifen (Soltamox) Mechanism

A

Competes with estradiol for binding to

estrogen receptor

9
Q

Tamoxifen (Soltamox) Therapeutics

A

ER-positive breast cancer, or as
adjuvant therapy following primary
breast tumor excision; prevention of
breast cancer in high-risk patients

10
Q

Tamoxifen (Soltamox) Important side effects

A

Hot flushes, hair loss; increased
risk of endometrial cancer;
increased risk of thromboembolic
events

11
Q

Tamoxifen (Soltamox) Other side effects

A

Nausea and vomiting

12
Q

Fulvestrant (Faslodex) Class

A

Selective
estrogen-receptor
downregulators
(SERDs)

13
Q

Fulvestrant (Faslodex) Mechanism

A

Binds with much higher affinity (>100-fold)
to estrogen receptor than tamoxifen,
inhibiting dimerization, increasing
degradation, and reducing overall ER levels

14
Q

Fulvestrant (Faslodex) Therapeutics

A

Posmenopausal women with ERpositive

metastatic breast cancer

15
Q

Aminoglutethamide (Cytadren) Class

A

Aromatase

inhibitors

16
Q

Aminoglutethamide (Cytadren) Mechanism

A

Inhibits function of aromatase

17
Q

Aminoglutethamide (Cytadren) Therapeutics

A

Relatively weak, used against breast

cancer

18
Q

Aminoglutethamide (Cytadren) Imp side effects

A

Significant

19
Q

Anastrozole (Arimidex) Class

A

Aromatase

inhibitors

20
Q

Anastrozole (Arimidex) Mechanism

A

Inhibits function of aromatase

21
Q

Anastrozole (Arimidex) Therapeutics

A

First-line for ER-positive breast cancer

in postmenopausal women

22
Q

Letrozole (Femara) class

A

Aromatase

inhibitors

23
Q

Letrozole (Femara) Mechanism

A

Inhibits function of aromatase

24
Q

Letrozole (Femara) Therapeutics

A

ER-positive breast cancer in

postmenopausal women

25
Q

Exemestane (Aromasin) class

A

Aromatase

inhibitors

26
Q

Exemestane (Aromasin) Mechanism

A

Steroidal inhibitor of aromatase

27
Q

Exemestane (Aromasin) Therapeutics

A

ER-positive breast cancer in

postmenopausal women

28
Q

Leuprolide (Lupron) class

A

GnRH analogs

29
Q

Leuprolide (Lupron) Mechanism

A

Binds GnRH receptor; inhibits release of

FSH & LH

30
Q

Leuprolide (Lupron) Therapeutics

A

Androgen ablation therapy, along with

AR blockers

31
Q

Goserelin (Zoladex) Class

A

GnRH analogs

32
Q

Goserelin (Zoladex) Mechanism

A

Binds GnRH receptor; inhibits release of

FSH & LH

33
Q

Goserelin (Zoladex) Therapeutics

A

Androgen ablation therapy, along with

AR blockers

34
Q

Flutamide (Eulexin) Class

A

Nonsteroidal
androgen-receptor
blockers

35
Q

Flutamide (Eulexin) Mechanism

A

Competes with androgen for AR binding

36
Q

Flutamide (Eulexin) Therapeutics

A

Androgen ablation therapy, along with

GnRH analogs

37
Q

Bicalutamide (Casodex) Class

A

Nonsteroidal
androgen-receptor
blockers

38
Q

Bicalutamide (Casodex) Mechanism

A

Competes with androgen for AR binding

39
Q

Bicalutamide (Casodex) Therapeutics

A

Androgen ablation therapy, along with

GnRH analogs